Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids.

[1]  Anneliese O. Speak,et al.  Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals , 2007, Proceedings of the National Academy of Sciences.

[2]  Anneliese O. Speak,et al.  Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency , 2007, Proceedings of the National Academy of Sciences.

[3]  Albert Bendelac,et al.  The biology of NKT cells. , 2007, Annual review of immunology.

[4]  N. Nagarajan,et al.  Invariant NKT Cells Amplify the Innate Immune Response to Lipopolysaccharide1 , 2007, The Journal of Immunology.

[5]  Chyung-Ru Wang,et al.  IFN-β-Mediated Up-Regulation of CD1d in Bacteria-Infected APCs1 , 2006, The Journal of Immunology.

[6]  R. Schreiber,et al.  Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[7]  S. Bolland,et al.  Nucleic Acid-Sensing TLRs as Modifiers of Autoimmunity1 , 2006, The Journal of Immunology.

[8]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[9]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[10]  I. Wilson,et al.  Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria , 2006, Nature Immunology.

[11]  R. Steinman,et al.  Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice , 2006 .

[12]  A. Landay,et al.  Activation of Plasmacytoid Dendritic Cells with TLR9 Agonists Initiates Invariant NKT Cell-Mediated Cross-Talk with Myeloid Dendritic Cells1 , 2006, The Journal of Immunology.

[13]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[14]  R. Medzhitov,et al.  Toll-dependent selection of microbial antigens for presentation by dendritic cells , 2006, Nature.

[15]  F. Platt,et al.  Activation of Invariant NKT Cells by the Helminth Parasite Schistosoma mansoni1 , 2006, The Journal of Immunology.

[16]  T. Giese,et al.  CpG ODN enhance antigen‐specific NKT cell activation via plasmacytoid dendritic cells , 2005, European journal of immunology.

[17]  Francesco Bertoni,et al.  Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells , 2005, Nature Immunology.

[18]  M. Foti,et al.  TLR-Dependent Activation Stimuli Associated with Th1 Responses Confer NK Cell Stimulatory Capacity to Mouse Dendritic Cells 1 , 2005, The Journal of Immunology.

[19]  S. Nutt,et al.  Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer , 2005, The Journal of experimental medicine.

[20]  L. Kaer,et al.  Innate Immunity: NKT Cells in the Spotlight , 2005, Current Biology.

[21]  A. Tonevitsky,et al.  Bacterial infections promote T cell recognition of self-glycolipids. , 2005, Immunity.

[22]  R. Brutkiewicz,et al.  Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d‐specific ligands for NKT cells , 2005, European journal of immunology.

[23]  D. Ho,et al.  Recognition of bacterial glycosphingolipids by natural killer T cells , 2005, Nature.

[24]  B. Beutler,et al.  Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections , 2005, Nature.

[25]  M. Smyth,et al.  Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.

[26]  S. Akira,et al.  Toll-like receptors in innate immunity. , 2004, International immunology.

[27]  R. Proia,et al.  Lysosomal Glycosphingolipid Recognition by NKT Cells , 2004, Science.

[28]  S. Akira,et al.  Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity , 2004, Cancer Research.

[29]  M. Kronenberg,et al.  Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.

[30]  R. Dwek,et al.  Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. , 2004, Analytical biochemistry.

[31]  D. Klinman.  Immunotherapeutic uses of CpG oligodeoxynucleotides , 2004, Nature Reviews Immunology.

[32]  R. Flavell,et al.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[33]  L. Kaer,et al.  NKT cells: what's in a name? , 2004, Nature Reviews Immunology.

[34]  L. Bry,et al.  Mechanism of CD1d-restricted natural killer T cell activation during microbial infection , 2003, Nature Immunology.

[35]  Michael T. Wilson,et al.  The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  N. Segal,et al.  Cross-presentation of Disialoganglioside GD3 to Natural Killer T Cells , 2003, The Journal of experimental medicine.

[37]  Jang-June Park,et al.  Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by β-d-glucosylceramide synthase deficiency , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Steinman,et al.  Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs , 2002, Nature Immunology.

[39]  P. Möller,et al.  Activating Immunity in the Liver. II. IFN-β Attenuates NK Cell-Dependent Liver Injury Triggered by Liver NKT Cell Activation1 , 2002, The Journal of Immunology.

[40]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[41]  B. Echtenacher,et al.  Antimetastatic effect of CpG DNA mediated by type I IFN. , 2001, Cancer research.

[42]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[43]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[44]  Seokmann Hong,et al.  CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. , 1997, Immunity.

[45]  K. Takeda,et al.  Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. , 1996, Journal of immunology.

[46]  R. Dwek,et al.  N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. , 1994, The Journal of biological chemistry.

[47]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.

[48]  T. Butters,et al.  Steps in the biosynthesis of mosquito cell membrane glycoproteins and the effects of tunicamycin. , 1981, Biochimica et biophysica acta.